15th Jun 2018 11:28
LONDON (Alliance News) - Silence Therapeutics PLC said Friday its compound for the treatment of iron overload disorders may "provide a safe, effective and patient-friendly therapeutic option".
Drug Discovery Project Leader Ute Schaeper said: "SLN124 shows dose-dependent and long-lasting effects on target levels as well as on modulation of iron stores and normalisation of erythropoiesis in relevant disease models."
The company said data on SLN124, designed to treat iron overload in conjunction with siRNA conjugate technology, shows it is a promising candidate for the treatment of iron overload and anaemia in beta-thalassemia and related disorders.
Silence Therapeutics shares were trading up 1.3% at 140.00 pence each.
Related Shares:
SLN.L